Amit Kakar will supervise a Singapore office that will spearhead the pharmaceutical company's corporate venturing investments across Asia.
Denmark-based pharmaceutical firm Novo plans to open an office in Singapore in August this year in order to oversee investments in Asia, it announced yesterday.
Although Novo Holdings, the holding company for the Novo Group, is an active investor in Europe and the United States, it has yet to participate in Asian deals, and the move is intended to support deals in Singapore, China, Japan and Southeast Asia.
The office will support corporate venturing subsidiary Novo Ventures, growth-stage unit Novo…
